Core Viewpoint - The company is set to present clinical data for ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st European Association for the Study of Diabetes (EASD) annual meeting in Vienna, Austria, highlighting its potential as a differentiated treatment for obesity [1] Group 1: Clinical Research and Development - ASC30 is currently undergoing a 28-day multiple ascending dose study (NCT06680440) [1] - The drug is characterized as a new chemical entity (NCE) with unique properties that allow for both oral and subcutaneous administration [1] - The compound is protected by patents in the U.S. and globally, with patent protection lasting until 2044, excluding any extensions [1] Group 2: Company Leadership and Vision - Dr. Wu Jinzi, the founder, chairman, and CEO of the company, expressed confidence that the efficacy and safety data presented will position ASC30 as a promising option for obesity treatment [1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), will present data on ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria [1] Summary by Relevant Sections Clinical Data Presentation - The presentation will include findings from a 28-day multiple ascending dose study (NCT06680440) of ASC30, highlighting its superior weight loss effects in obese subjects [1] - The abstract title for the discussion is "ASC30, an oral GLP-1R biased small molecule agonist shows superior weight loss effects in obese subjects: a 28-day multiple ascending dose study" [1] Event Details - The discussion will take place on September 16, 2025, from 12:00 to 13:00 (Central European Summer Time) [1] - The report number for this presentation is 827 [1] Company Perspective - Dr. Wu Jinzi, founder, chairman, and CEO of the company, expressed anticipation for showcasing the clinical data at the EASD meeting, believing that the efficacy and safety data will position ASC30 as a differentiated treatment option for obesity [1]

Core Viewpoint - The company is set to present clinical data for ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st European Association for the Study of Diabetes (EASD) annual meeting in Vienna, Austria, highlighting its potential as a differentiated treatment for obesity [1] Company Summary - The CEO of the company, Dr. Wu Jinzi, expressed optimism about the clinical efficacy and safety data for ASC30, suggesting it could become a unique solution for obesity treatment [1] - ASC30 is a new chemical entity (NCE) with both oral and subcutaneous administration capabilities, supported by patent protection in the U.S. and globally until 2044, excluding any patent extensions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 歌禮將在第61屆歐洲糖尿病研究協會(EASD)年會上報告ASC30 口服小分子GLP-1R激動劑28天多劑量遞增研究結果 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣布，將在奧地利維也納舉行的第61屆歐洲 糖尿病研究協會(EASD)年會上的簡短口頭討論中報告ASC30口服小分子GLP-1受 體(GLP-1R)激動劑28天多劑量遞增研究(NCT06680440)數據。 簡短口頭討論細節 「我們期待在今年的EASD年會上向業界展示ASC30口服片的臨床數據，」歌禮創 始人、董事會主席兼首席執行官吳勁梓博士表示，「我們相信這些療效和安全性數 據 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 歌禮製藥有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,000,000,000 | USD | | 0.0001 | USD | | 700,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 7,000,000,000 | USD | | 0.0001 | USD | | 700,000 | 本月底法定/註冊股本總額： USD 700,000 FF3 ...

Major Events - Sihuan Pharmaceutical Holdings Group Ltd. successfully administered the first human dose of the new radiopharmaceutical conjugate drug 3D1015 [1] - Shenzhen International's joint venture Shenzhen Airlines plans to raise a total of 16 billion yuan in a phased capital increase [1] - Kangzheng Pharmaceutical received clinical trial approval for its innovative oral small molecule JAK1 inhibitor Povorcitinib for indications of vitiligo and suppurative hidradenitis [1] - Ruihe Digital signed a framework agreement with Tielin Superlight Technology to jointly advance the business of real-world asset tokenization [1] - Zhongxu Future will operate and launch a new mobile game "Miracle MU" titled "New Moon Continent" [1] Financial Performance - Noah Holdings reported a net profit attributable to shareholders of 179 million yuan for Q2, a year-on-year increase of 79% driven by strong growth in investment product distribution [1] - Trip.com Group reported a net profit of 4.846 billion yuan for Q2, an increase of 26.43% year-on-year [1] - Shijiazhuang Pharmaceutical Group announced a mid-year profit attributable to equity holders of approximately 283.5 million HKD, a year-on-year decrease of about 58.7% [1] - Zhongsheng Holdings reported a mid-year profit attributable to shareholders of 1.011 billion yuan, a decrease of 36% year-on-year [1] - SF Express City reported an adjusted net profit of approximately 160 million yuan, a year-on-year increase of 139% [1] - Baidu's subsidiary reported a mid-year profit attributable to shareholders of 47.999 million yuan, returning to profitability [1] - Li Auto reported a net profit of 1.093 billion yuan for Q2, a decrease of 0.91% year-on-year [1] - Shanghai Industrial Holdings reported a mid-year profit attributable to shareholders of 1.042 billion HKD, with an interim dividend of 0.42 HKD per share [1] - Beijing Holdings reported a mid-year profit attributable to shareholders of 3.404 billion yuan, an increase of 8.07% year-on-year [1] - Qingdao Port reported a net profit of 2.842 billion yuan, a year-on-year increase of 7.58% [1] - New China Life Insurance reported a net profit of 14.799 billion yuan, a year-on-year increase of 33.5% [1] - China Galaxy Securities reported a net profit of 6.488 billion yuan, a year-on-year increase of 47.86% [1] - China Taiping reported a 12.2% increase in shareholder profit, with a nearly 23% high growth in life insurance new business value [1] - China Resources Gas reported a mid-year profit attributable to shareholders of 2.403 billion HKD, a year-on-year decrease of 30.5% [1] - SF Holding reported a net profit of 5.738 billion yuan, a year-on-year increase of 19.37%, with volume growth exceeding the overall express delivery industry [1] - SMIC reported a net profit of approximately 320 million USD, a year-on-year increase of 35.6% [1] - SenseTime reported a revenue growth of 35.6% year-on-year, reaching 2.358 billion yuan [1] - BeiGene reported a net profit of 95.59 million USD, returning to profitability [1] - Fubo Group reported a mid-year net profit exceeding 100 million, driven by AI [1] - CITIC Securities reported a net profit of 13.719 billion yuan, a year-on-year increase of 29.79% [1] - Huadian International Power reported a net profit of 3.904 billion yuan, a year-on-year increase of 13.15% [1] Additional Financial Performance - Zhou Hei Ya reported a mid-year profit attributable to shareholders of 108 million yuan, a year-on-year increase of 228% [2] - Haitian Flavoring reported a net profit of 3.91 billion yuan, a year-on-year increase of 13.3% [2] - Dasheng Holdings reported a mid-year adjusted net profit growth of 79.6% driven by store expansion and membership growth [2] - CITIC Securities reported a net profit of 4.509 billion yuan, a year-on-year increase of 57.77% [2] - Huitongda reported a mid-year profit attributable to shareholders of 13.9 million yuan, a year-on-year increase of 10.81% [2] - Yunfeng Financial reported a mid-year profit attributable to shareholders of 486 million HKD, a year-on-year increase of 142.04% [2] - Jiufang Zhitu reported a mid-year profit attributable to shareholders of 865 million yuan, returning to profitability [2] - Air China reported a net loss of approximately 1.806 billion yuan, a year-on-year narrowing of 35.11% [2] - ZTE reported a net profit of approximately 5.058 billion yuan, a year-on-year decrease of 11.77% [2] - China Merchants Securities reported a net profit of 5.186 billion yuan, a year-on-year increase of 9.23% [2] - Datang Power reported a net profit of approximately 4.874 billion yuan, a year-on-year increase of 50.3% [2] - China Pacific Insurance reported a net profit of 27.885 billion yuan, a year-on-year increase of 11% [2] - Beijing Capital International Airport reported a post-tax loss of 164 million yuan, a year-on-year narrowing of 56.48% [2] - Dongguan Rural Commercial Bank reported a mid-year net profit of 2.629 billion yuan [2] - Shenzhen Holdings reported a mid-year loss attributable to shareholders of 2.618 billion HKD, a year-on-year increase of 137.76% [2] - China Southern Airlines reported a net loss of 1.534 billion yuan, a year-on-year increase of 45.54% [2] - COSCO Shipping Holdings reported a profit attributable to shareholders of 17.528 billion yuan, a year-on-year increase of 3.9% [2] - Guofu Hydrogen Energy reported revenue of 10.9 million yuan, actively expanding overseas cooperation and business layout [2] - Kangsheng Global reported a mid-year gross profit of 197 million yuan, with stable progress across all businesses [2] - Dongfang Electric reported a net profit of 1.91 billion yuan, a year-on-year increase of 12.91%, maintaining the industry's leading market share in nuclear and gas power [2] - Eagle Eye Technology reported a profit of 443,000 yuan, returning to profitability [2] - Haier Smart Home reported a profit attributable to shareholders of 12.033 billion yuan, a year-on-year increase of 15.6% [2] - EDA Group Holdings reached a partnership agreement with UTCPAY to collaborate in digital asset trading, Web3 technology, and blockchain applications [2] - Gilead Sciences reported that ASC30 oral tablets showed good and differentiated pharmacokinetic characteristics in the U.S. Phase Ib multi-dose escalation study [2]

Core Insights - The announcement from the company indicates positive topline pharmacokinetic (PK) data from the Phase Ib multiple ascending dose (MAD) study of ASC30 in obese subjects with a BMI of 30-40 kg/m² [1] Group 1: Study Results - The study involved a randomized, double-blind, placebo-controlled design [1] - In cohort 1 (20 mg), the drug exposure at steady state reached 3560 ng.h/mL, while in cohort 2 (40 mg), it reached 5060 ng.h/mL [1] - After 28 days of treatment, the average weight loss was 4.5% for cohort 1 and 6.5% for cohort 2, indicating that higher drug exposure correlates with more significant weight loss effects [1]

Core Insights - The announcement from the company indicates positive topline pharmacokinetic (PK) data for ASC30, an oral tablet administered once daily, in a Phase Ib multiple ascending dose (MAD) study involving obese subjects [1][2][3] - The study demonstrated that higher drug exposure levels correlate with more significant weight loss, with a 4.5% reduction in the 20 mg cohort and a 6.5% reduction in the 40 mg cohort after 28 days of treatment [1][3] Group 1: Drug Exposure and Weight Loss - In the Phase Ib MAD study, ASC30 drug exposure levels (AUC0-24h) reached 3,560 ng.h/mL for the 20 mg cohort and 5,060 ng.h/mL for the 40 mg cohort, showing a direct relationship with weight loss outcomes [1] - Comparative analysis revealed that ASC30's drug exposure was approximately 2.3 times and 3.3 times higher than orforglipron's exposure at 24 mg, which resulted in a weight loss of only 3.6% [2] Group 2: Safety and Tolerability - The ASC30 oral tablet demonstrated good safety and tolerability, with no serious adverse events (SAEs) reported and no grade 3 or higher adverse events, including gastrointestinal issues [3] - Laboratory tests and vital signs showed no abnormalities, and there were no elevations in liver enzymes during the treatment period [3] Group 3: Competitive Positioning - The company believes that the higher drug exposure levels of ASC30 will lead to more significant weight loss effects compared to small molecule GLP-1 receptor agonists, including orforglipron [3] - The CEO expressed excitement over the data indicating ASC30's competitive and differentiated potential in treating obesity, based on its superior pharmacokinetic profile [3]

Core Insights - The core point of the article is that Gilead Sciences-B (01672.HK) announced positive results for its ASC30 oral tablet in a Phase Ib multi-dose escalation study in the U.S., demonstrating favorable pharmacokinetic characteristics compared to orforglipron [1] Group 1: Drug Performance - ASC30 shows a drug exposure level approximately 2.3 to 3.3 times higher than orforglipron, indicating a significant advantage in pharmacokinetics [1] - The higher drug exposure and good tolerability of ASC30 suggest it may be more effective than orforglipron [1] Group 2: Future Research - Gilead plans to conduct a Phase IIa study of ASC30 in overweight or obese subjects, with top-line data expected in the fourth quarter of 2025 [1]

Core Insights - The announcement from the company indicates positive topline pharmacokinetic (PK) data for ASC30, an oral tablet administered once daily, in a Phase Ib multiple ascending dose (MAD) study involving obese subjects with a BMI of 30-40 kg/m² [1][2] - The study demonstrated that higher drug exposure levels correlate with more significant weight loss, with a 4.5% reduction in weight for the 20 mg cohort and a 6.5% reduction for the 40 mg cohort after 28 days of treatment [1][3] Group 1: Pharmacokinetics and Weight Loss - In the Phase Ib MAD study, the drug exposure levels (AUC0-24h) for the 20 mg and 40 mg cohorts were 3,560 ng.h/mL and 5,060 ng.h/mL, respectively [1] - The weight loss results were consistent with the drug exposure levels, indicating that higher exposure leads to more pronounced weight loss effects [1][3] Group 2: Comparison with Orforglipron - ASC30's drug exposure levels were approximately 2.3 times and 3.3 times higher than those of orforglipron (24 mg cohort), which had an AUC0-24h of 1,520 ng.h/mL [2] - The weight loss achieved with orforglipron after 28 days was only 3.6%, indicating that ASC30 may offer superior efficacy in weight reduction [2] Group 3: Safety and Tolerability - The ASC30 oral tablet demonstrated good safety and tolerability, with no serious adverse events (SAEs) reported and no grade 3 or higher adverse events observed [3] - No elevations in liver enzymes or other abnormalities were noted during the study, suggesting a favorable safety profile for ASC30 [3] Group 4: Competitive Positioning - The company believes that the higher drug exposure levels of ASC30 will lead to more significant weight loss compared to other small molecule GLP-1 receptor agonists, including orforglipron [3] - The data from non-human primate studies, which showed higher drug exposure for ASC30, has been successfully translated into human clinical research, enhancing the competitive and differentiated potential of ASC30 in treating obesity [3]